What is Fondaparinux?
Fondaparinux is a synthetic polysaccharide anticoagulant that selectively inhibits activated Factor X (FXa) [1]. It is administered by subcutaneous injection [1].
How does Fondaparinux work?
Fondaparinux mimics the action of naturally occurring antithrombin III. By binding to antithrombin III, fondaparinux greatly enhances its ability to inactivate FXa [1]. FXa is a critical enzyme in the coagulation cascade, and its inhibition prevents the conversion of prothrombin to thrombin, thus reducing fibrin formation and clot development [1].
What is Fondaparinux used for?
Fondaparinux is used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing abdominal surgery, hip fracture surgery, or chronic knee replacement surgery [1]. It is also used for the treatment of DVT and PE in patients who have not taken an oral anticoagulant [1].
When does Fondaparinux patent exclusivity expire?
Information on specific patent expiry dates for fondaparinux can be found on DrugPatentWatch.com [1].
What are the potential side effects of Fondaparinux?
The most common side effect associated with fondaparinux is bleeding [1]. Other potential side effects include anemia, nausea, and insomnia [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternatives to Fondaparinux?
Other anticoagulants, such as unfractionated heparin, low molecular weight heparins (e.g., enoxaparin), and direct oral anticoagulants (DOACs), are available for the prevention and treatment of thromboembolic events [2]. The choice of anticoagulant depends on the patient's clinical condition, risk factors, and other individual considerations [2].
What is the pricing for Fondaparinux?
Pricing for fondaparinux can vary based on factors such as dosage, quantity, and pharmacy. For current pricing information, consulting a pharmacy or a drug pricing resource is recommended.
Are there biosimilars for Fondaparinux?
The availability of biosimilars for fondaparinux is influenced by patent status and regulatory approvals. Information regarding biosimilar development and availability can be accessed through resources like DrugPatentWatch.com [1].
Who manufactures Fondaparinux?
The primary manufacturer of fondaparinux is GlaxoSmithKline, under the brand name Arixtra [3].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.uptodate.com/contents/overview-of-the-management-of-venous-thromboembolism
3. https://www.rxlist.com/arixtra-drug.htm